Sanofi and Regeneron Hit Asthma Phase III Endpoints With Dupixent

 
• By Alexandra Shimmings

Dupixent has upped the ante on Nucala and Cinqair, showing broad activity in Phase III in asthma. But will it be bested by AstraZeneca and Amgen's tezepelumab?

Peacock
Sanofi and Regeneron's Expanding Pipeline Pride • Source: Shutterstock

More from Clinical Trials

More from R&D